港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,787.578

-5.464-0.30%

漲家數：2

跌家數：4

平家數：2

市盈率：- -

高：1,840.451

開：1,793.941

低：1,762.516

收：1,793.042

資料載入中...

荃信生物(02509.HK)QX002N治療脊柱炎III期臨牀試驗達主要終點

阿斯达克财经

港股CRO板塊遭重挫，康龍化成一天跌了26億港元，去年扣非淨利現近10年首次同比下滑

板塊普跌！“藥明系”股價大挫，發生了什麼？

荃信生物-B：QX002N治療強直性脊柱炎的III期臨牀試驗達到主要終點

荃信生物-B(02509)：QX002N治療強直性脊柱炎的III期臨牀試驗達到主要終點

康龍化成收盤下跌3.14%，滾動市盈率26.82倍，總市值505.19億元

港股CXO板塊遇冷藥明康德跌超10%

康希諾生物(06185)：DTcP-Hib-MCV4聯合疫苗在中國獲臨牀試驗批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=13"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1787.5779,"timestamp":1741594084354,"preClose":1793.0419,"halted":0,"volume":80771814,"delay":0,"changeRate":-0.003047,"change":-5.463989,"pbRate":2.65369,"amount":1784097230,"amplitude":0.043465,"prevYearClose":1395.7731,"fiveDayClose":1689.63,"twentyDayClose":1618.242,"turnoverRate":0.006914,"marketCap":379404801152,"floatMarketCap":166674436992,"peRate":33.079805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1840.4508,"amplitude":0.043465,"preClose":1793.0419,"low":1762.5157,"pbRate":"2.65369","latestPrice":1787.5779,"volume":80771814,"delay":0,"open":1793.9412,"prevYearClose":1395.7731,"prevWeekClose":1793.042,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1689.63,"twentyDayClose":1618.242,"sixtyDayClose":1409.843,"secType":"PLATE","market":"HK","turnoverRate":0.006914,"peRate":33.079805,"marketCap":379404801152,"floatMarketCap":166674436992,"timestamp":1741594084354,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":2,"down":4,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:13,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2513773337","title":"荃信生物(02509.HK)QX002N治療脊柱炎III期臨牀試驗達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2513773337","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513773337?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 23:40","pubTimestamp":1740411600,"startTime":"0","endTime":"0","summary":"荃信生物－Ｂ(02509.HK) 公布，公司自主研发的QX002N注射液用于治疗强直性脊柱炎的III期临床试验达到主要终点。数据显示，QX002N在中重度活动性强直性脊柱炎患者中展出优异的疗效以及良好的安全性和耐受性。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240325152227966_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240325152227966_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1419763/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1576","BK1583","BK1141","BK1161","03347","02509"],"gpt_icon":0},{"id":"2513230757","title":"港股CRO板塊遭重挫，康龍化成一天跌了26億港元，去年扣非淨利現近10年首次同比下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2513230757","media":"时代财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513230757?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 20:27","pubTimestamp":1740400029,"startTime":"0","endTime":"0","summary":"作为国内CRO龙头，康龙化成披露的2024年业绩预告显示，公司的扣非净利润在近10年来首次出现同比下滑。2024年，康龙化成预计共有非经常性损益6.6亿元～7.1亿元，而2023年的非经常性损益仅有8722.56万元。扣除这部分收益后，2024年康龙化成的扣非净利润则预计同比下降24%～29%。实际上，对比历年数据来看，康龙化成的业绩增幅从2022年开始出现下滑，2022年扣非净利润的同比增长仅有个位数，为6.01%，而这一数字在2021年为同比增长67.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224202826962e78f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224202826962e78f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","03759","07226","HSCEI","BK1576","HSTECH"],"gpt_icon":0},{"id":"2513726528","title":"板塊普跌！“藥明系”股價大挫，發生了什麼？","url":"https://stock-news.laohu8.com/highlight/detail?id=2513726528","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513726528?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 19:45","pubTimestamp":1740397533,"startTime":"0","endTime":"0","summary":"2月24日，港、A两市的医药外包概念遭遇普跌。其中，A股市场的药明康德（603259.SH）大跌7.02%，泰格医药（300347.SZ）、康龙化成（300759.SZ）、凯莱英（002821.SZ）也都遭遇下挫。","market":"other","thumbnail":"https://images.finet.hk/photoLib/title/202502_1/1aa95f2c-670c-4686-9009-5d5ad019f5e1.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202502_1/1aa95f2c-670c-4686-9009-5d5ad019f5e1.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67bc5bdd2308296b6a5cceda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["06127","LU0856984785.SGD","09939","LU1720050803.USD","LU0051755006.USD","LU1242518857.USD","LU0572944931.SGD","LU0456827905.SGD","IE00B0JY6N72.USD","LU0979878070.USD","LU0516423091.SGD","LU0348735423.USD","BK1161","LU0181495838.USD","LU2039709279.SGD","LU0516423174.USD","02269","LU0516422952.EUR","BK1583","LU2045819591.USD","LU0819121731.USD","BK1589","LU1046422090.SGD","LU0516422366.SGD","BK1574","BK1576","BK1141","03759","LU1880383366.USD","LU0307460666.USD","BK1610","SG9999002562.SGD","SG9999002463.SGD","02359","LU0359201612.USD","LU0417516902.SGD","LU0456846285.SGD","03347","LU1688375341.USD","LU0043850808.USD","LU0327786744.USD","LU0348825331.USD","LU0320764599.SGD","LU0326950275.SGD","LU0823426308.USD","LU0516422440.USD","LU0140636845.USD","LU0039217434.USD","LU1242518931.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2513700746","title":"荃信生物-B：QX002N治療強直性脊柱炎的III期臨牀試驗達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2513700746","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513700746?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 18:35","pubTimestamp":1740393316,"startTime":"0","endTime":"0","summary":"格隆汇2月24日丨荃信生物-B发布公告，公司自主研发的QX002N注射液用于治疗强直性脊柱炎的III期临床试验达到主要终点。数据显示，QX002N在中重度活动性强直性脊柱炎患者中展出优异的疗效以及良好的安全性和耐受性。同时，其参与骨重塑的调节机制，被确定为强直性脊柱炎发病的主要因素。QX002N注射液用于治疗AS的III期临床试验达到主要终点是该项目的重要阶段性成果，公司将积极推进后续研发工作，并根据研发进展情况及时进行信息披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224183516abdac422&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224183516abdac422&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","03347","BK1583","02509","BK1141","BK1576"],"gpt_icon":0},{"id":"2513474746","title":"荃信生物-B(02509)：QX002N治療強直性脊柱炎的III期臨牀試驗達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2513474746","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513474746?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 18:33","pubTimestamp":1740393190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，本公司自主研发的QX002N注射液用于治疗强直性脊柱炎(ankylosing spondylitis, AS)的 III期临床试验达到主要终点。数据显示， QX002N在中重度活动性强直性脊柱炎患者中展出优异的疗效以及良好的安全性和耐受性。本次试验是由北京协和医院曾小峰教授牵头开展的一项在活动性强直性脊柱炎患者中评价QX002N注射液的疗效和安全性的多中心、随机、双盲、安慰剂对照的III 期临床研究，目前已完成首次分析。研究共纳入641例中重度活动性强直性脊柱炎受试者，其中QX002N组322例，安慰剂组319例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1161","BK1576","BK4134","III","BK1141","BK1583","02509"],"gpt_icon":0},{"id":"2513439307","title":"康龍化成收盤下跌3.14%，滾動市盈率26.82倍，總市值505.19億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513439307","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513439307?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 17:41","pubTimestamp":1740390119,"startTime":"0","endTime":"0","summary":"2月24日，康龙化成今日收盘28.41元，下跌3.14%，滚动市盈率PE达到26.82倍，总市值505.19亿元。从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均49.02倍，行业中值46.24倍，康龙化成排名第20位。资金流向方面，2月24日，康龙化成主力资金净流出10254.02万元，近5日总体呈流入状态，5日共流入1074.99万元。最新一期业绩显示，2024年三季报，公司实现营业收入88.17亿元，同比3.00%；净利润14.22亿元，同比24.82%，销售毛利率33.87%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/24174148346824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0216","03759","BK1141","300759","BK1576"],"gpt_icon":0},{"id":"2513126710","title":"港股CXO板塊遇冷 藥明康德跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513126710","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513126710?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 17:06","pubTimestamp":1740387979,"startTime":"0","endTime":"0","summary":"2月24日，港股市场CXO板块遭遇重挫。截至收盘，康龙化成（03759）跌超7%、维亚生物（01873）、药明生物（02269）跌超9%，药明康德（02359）跌超10%、方达控股（01521）下跌近14%，板块整体跑输恒生指数。市场分析指出，此次调整主要受海外市场情绪传导影响，部分国际资金近期对生物科技产业链持审慎态度，叠加CXO板块前期估值较高，加剧资金获利了结意愿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202502243327787895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0708995583.HKD","LU2125910500.SGD","LU2045819591.USD","LU0052750758.USD","LU0320764599.SGD","02359","LU2242644610.SGD","HSCEI","CXO","HSTECH","BK1583","BK1576","YANG","LU1046422090.SGD","BK1141"],"gpt_icon":0},{"id":"2513710377","title":"康希諾生物(06185)：DTcP-Hib-MCV4聯合疫苗在中國獲臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2513710377","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513710377?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 17:05","pubTimestamp":1740387943,"startTime":"0","endTime":"0","summary":"于本公告日期，作为DTcP-Hib-MCV4联合疫苗的组成部分，公司的国内首个脑膜炎球菌四价结合疫苗产品曼海欣已获得药品注册证书并商业化，婴幼儿用DTcP处于III期临床阶段，Hib疫苗处于I期临床阶段。基于上述疫苗开发过程中所累积的相关数据，公司拟研发DTcP-Hib-MCV4联合疫苗，满足市场对多联疫苗的需求，并形成差异化竞争。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","BK1583","BK1161","BK1574","BK1576","06185","BK1141","03347"],"gpt_icon":0}],"pageSize":16,"totalPage":13,"pageCount":13,"totalSize":200}]}}